Clinical trial
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00309959 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00309959 |
|---|---|
| Title | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis |
| Enrollment | 37 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2011 |
| First posted | Apr 3, 2006 |
| Last update posted | Jan 8, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: